Obstetrics and Gynecology and Women's Health—2nd Edition

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Sex, Gender and Hormone Based Medicine".

Deadline for manuscript submissions: 31 January 2025 | Viewed by 310

Special Issue Editor


E-Mail
Guest Editor

Special Issue Information

Dear Colleagues,

Uterine myomas occur in approximately one third of women of reproductive age. They are considered the primary cause of infertility in 1–3% of cases; however, this is the case in approximately 5–10% of young women with fertility problems. Although the malignant transformation of myomas is extremely rare, they are associated with significant morbidity, and are the most common indication for the requirement of a hysterectomy. Worldwide, they represent a major public and personal health concern. Uterine myomas are a phenotype of various genetic diseases associated with a variety of different types, progressions, and outcomes in different ethnic groups. Recent research on the pathogenesis and pathophysiology of myomas based on cellular and molecular biology is enabling us to better understand this issue, yet a lot of further work is required. This Special Issue, entitled “Obstetrics and Gynecology and Women`s Health”, is devoted to myomas, aiming to provide an overview of new aspects of conservative medical treatment options which preserve the uterus in the face of symptomatic myomas and surgical therapy modalities.

Prof. Dr. Panagiotis N. Tsikouras
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • uterine fibroids
  • uterine myoma
  • leiomyoma
  • uterine artery embolization
  • endometriosis
  • gynecological surgery
  • infertility
  • endocrinology
  • hysteroscopy
  • hormonal therapies
  • personalized medicine

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 435 KiB  
Review
Diagnosis, Prevention, and Management of Fetal Growth Restriction (FGR)
by Panagiotis Tsikouras, Panos Antsaklis, Konstantinos Nikolettos, Sonia Kotanidou, Nektaria Kritsotaki, Anastasia Bothou, Sotiris Andreou, Theopi Nalmpanti, Kyriaki Chalkia, Vlasis Spanakis, George Iatrakis and Nikolaos Nikolettos
J. Pers. Med. 2024, 14(7), 698; https://doi.org/10.3390/jpm14070698 - 28 Jun 2024
Viewed by 218
Abstract
Fetal growth restriction (FGR), or intrauterine growth restriction (IUGR), is still the second most common cause of perinatal mortality. The factors that contribute to fetal growth restriction can be categorized into three distinct groups: placental, fetal, and maternal. The prenatal application of various [...] Read more.
Fetal growth restriction (FGR), or intrauterine growth restriction (IUGR), is still the second most common cause of perinatal mortality. The factors that contribute to fetal growth restriction can be categorized into three distinct groups: placental, fetal, and maternal. The prenatal application of various diagnostic methods can, in many cases, detect the deterioration of the fetal condition in time because the nature of the above disorder is thoroughly investigated by applying a combination of biophysical and biochemical methods, which determine the state of the embryo–placenta unit and assess the possible increased risk of perinatal failure outcome and potential for many later health problems. When considering the potential for therapeutic intervention, the key question is whether it can be utilized during pregnancy. Currently, there are no known treatment interventions that effectively enhance placental function and promote fetal weight development. Nevertheless, in cases with fetuses diagnosed with fetal growth restriction, immediate termination of pregnancy may have advantages not only in terms of minimizing perinatal mortality but primarily in terms of reducing long-term morbidity during childhood and maturity. Full article
(This article belongs to the Special Issue Obstetrics and Gynecology and Women's Health—2nd Edition)
Back to TopTop